Research

SK Biopharma, Proen team up to develop new radiopharmaceuticals

Tue, 17 Dec 2024 12:00:00 -0500

SK Biopharmaceuticals Co. Ltd. and Proen Therapeutics Co. Ltd. joined hands in a research collaboration to advance up to two preclinical small protein-based radiopharmaceuticals by 2027 – the year SK Biopharmaceuticals aims to “become a leading radiopharma player” worldwide.

Prime’s $3.61B Bristol Myers deal is year’s fourth largest

Tue, 01 Oct 2024 09:00:00 -0400

In the year’s fourth-largest deal, Prime Medicine Inc. will collaborate with Bristol Myers Squibb Co. in a research collaboration and license agreement totaling $3.61 billion. The two companies plan to develop reagents for ex vivo T-cell therapies. While the programs and targets have yet to be disclosed, BMS is expanding its CAR T development, begun more than five years ago, with this deal.

Prime’s $3.61B Bristol Myers deal is year’s fourth largest

Mon, 30 Sep 2024 12:00:00 -0400

Medtronic’s Hong says humans need to remain in control of AI

Tue, 31 Oct 2023 12:00:00 -0400

As more and more artificial intelligence (AI)-based solutions get developed to improve patient care, humans should ultimately remain in control because no AI system will be free from mistakes, said Ha Hong, Chief Artificial Intelligence Officer in Medtronic plc’s Endoscopy unit. “There will be some errors, it is simply not possible to create a system that is 100% error free,” he told BioWorld in an interview.

Lifearc to put £100M into rare diseases translational research

Wed, 12 Jul 2023 12:00:00 -0400

The U.K. medical research charity Lifearc has launched the first part of a £100 million (US$130 million) plan to promote translation of biomedical research into therapies for rare diseases, opening the program with a £2.5 million call for projects to repurpose existing drugs to treat the debilitating inherited skin disease epidermolysis bullosa (EB).

Doudna, Banfield lead $70M research initiative on CRISPR-based microbiome engineering

Tue, 18 Apr 2023 12:00:00 -0400

A research initiative led by Jennifer Doudna and Jill Banfield of the Innovative Genomics Institute at the University of California, Berkeley, has landed $70 million in funding from the Audacious Project to bring the power and precision of CRISPR-based genome editing to the gut microbiome of humans and animals, in an ambitious effort to engineer complex microbial communities to achieve outcomes that can benefit human health and the environment.

Gandeeva and Moderna enter research collaboration using AI-enabled cryogenic electron microscopy

Fri, 31 Mar 2023 09:00:00 -0400

Gandeeva Therapeutics Inc. has entered into a research collaboration with Moderna Inc. to...

Incyte to leverage Caris’ molecular science and technology solutions to support oncology R&D

Wed, 08 Mar 2023 09:00:00 -0500

Caris Life Sciences Inc. has entered into a strategic research partnership with Incyte Corp. to...

Miromatrix, Baxter partner on bioengineered liver replacement system

Wed, 01 Feb 2023 13:00:00 -0500

Baxter International Inc. has joined forces with Miromatrix Medical Inc. to advance the development of bioengineered organs for patients with acute liver failure (ALF). Under the collaborative research agreement, Baxter will combine its Prismax system with Miromatrix's single-use bioengineered liver, miroliver, to provide external support to patients' native livers as they await transplant or potential regeneration.

Our Future Health: UK-launched effort to boost health research and discovery

Wed, 26 Oct 2022 12:00:00 -0400

The U.K. is launching a £230 million (US$260 million) project to build a database linking the health records and genetic information of 5 million people, which will be open for discovery research and as a source of clinical trial recruits for academics and companies.

Our Future Health: UK-launched effort to boost health research and discovery

Tue, 25 Oct 2022 12:00:00 -0400

Fungi finder Lifemine brings in a series C and a GSK R&D deal

Wed, 23 Mar 2022 12:00:00 -0400

Fungal biosphere specialist Lifemine Therapeutics Inc. has struck a goldmine through a $175 million series C financing and an R&D collaboration allowing Glaxosmithkline plc (GSK) to use the company's platform to identify small-molecule leads.

Australia launches first biotech incubator with AU$40M to give research commercial boost

Tue, 16 Nov 2021 12:58:00 -0500

PERTH, Australia – Australia’s Medical Research Future Fund is pumping AU$40 million (US$29 million) into a national biotech incubator program called CUREator to fund early stage novel therapeutics and preclinical medical research.

Australia launches first biotech incubator with AU$40M to give research commercial boost

Fri, 12 Nov 2021 12:00:00 -0500

EACH lobbies for comprehensive EU cardiovascular disease policy

Mon, 27 Sep 2021 13:00:00 -0400

LONDON – Industry groups, patients’ representatives and clinicians have launched the European Alliance for Cardiovascular Health (EACH) to lobby for a comprehensive EU policy to address the increasing burden of cardiovascular disease.

Compass explores psychedelic meds with UK institutions

Tue, 06 Jul 2021 12:00:00 -0400

Compass Pathways Ltd. has joined with a U.K. hospital and an academic establishment to research the role of psychedelic medicine in new models of mental health care. The London-based company signed a memorandum of understanding with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology and Neuroscience at King’s College London to launch the project.

$1.225B Biobucks: Mina banks $25M up front as Lilly buys into saRNA tech in five-target deal

Tue, 11 May 2021 01:00:00 -0400

DUBLIN – Mina Therapeutics Ltd. continues to make progress in its long-term ambition to establish small activating RNA (saRNA) as a new therapeutic modality. The biotech has now entered a multitarget research collaboration with Eli Lilly and Co., in which it is receiving $25 million up front and up to $245 million in development and commercial milestones per product.

Scenic nabs Genentech as first partner for genetic modifier efforts

Mon, 21 Sep 2020 12:00:00 -0400

LONDON - Scenic Biotech BV has signed up Genentech as first partner for its high-throughput platform for identifying genetic modifiers that can suppress or even completely block the effect of a disease-causing mutated gene, as starting points for drug discovery and development. Under the terms of the agreement, Scenic will identify modifiers in undisclosed therapeutic areas, with Genentech, part of the Roche Group, having an option to take multiple targets into development.

Harbour Biomed signs research deal for COVID-19 treatment and files listing application

Tue, 25 Aug 2020 15:10:00 -0400

HONG KONG – Last week was a busy one for Harbour Biomed Therapeutics Ltd., seeing the company sign a COVID-19 research collaboration with several Dutch institutions as well as lodge an application to list on the Hong Kong Stock Exchange.

Harbour Biomed signs research deal for COVID-19 treatment and files listing application

Mon, 24 Aug 2020 12:00:00 -0400

‘Shrinking’ Horizon as EU leaders cut R&D funding even as researchers fight pandemic

Fri, 24 Jul 2020 12:00:00 -0400

LONDON – Research and health emerged as the biggest losers following a marathon four days of negotiations by EU leaders on the bloc’s €1.1 trillion (US$1.3 trillion) 2021 - 2027 budget and the formation of a €750 billion (US$872 billion) pandemic recovery fund. Rather than €94.4 billion over the next seven years as proposed, the R&D program Horizon Europe, will get €80.9 billion.

Roche, Boehringer Ingelheim push further into China

Tue, 14 Jul 2020 13:28:00 -0400

HONG KONG- Boehringer Ingelheim International GmbH and Roche Holding AG have announced new initiatives to seek R&D collaborations in China, increasing both their footprint in China and China’s global biopharma presence. Boehringer Ingelheim announced earlier this month the launch of an External Innovation Hub in Shanghai. Meanwhile, Roche China also launched a collaboration initiative this week to develop therapies for gastrointestinal cancer.

Roche, Boehringer Ingelheim push further into China

Mon, 13 Jul 2020 12:00:00 -0400

Medtronic to get $337M from Blackstone for diabetes R&D in exchange for royalties

Mon, 15 Jun 2020 12:00:00 -0400

Royalty deals by an investor into a particular pharmaceutical company program are not unheard of. This structure allows the investor to secure a portion of that specific anticipated upside, while enabling the pharma to fully fund R&D for that program without having to sacrifice other priorities to do so.

Innovent partners with Roche in multibillion-dollar deal targeting bispecifics, cell therapies

Tue, 09 Jun 2020 13:00:00 -0400

BEIJING – Suzhou, China-based Innovent Biologics Inc. is known in China as one of the first drugmakers to launch a PD-1 monoclonal antibody. Now, the company is moving to expand its product portfolio and enhance efforts in developing bispecific antibodies and cell therapies in a potential multibillion-dollar deal with pharma giant Roche Holding AG.

Edigene, Immunochina betting on allogeneic CAR T therapy in cancer collaboration

Tue, 02 Jun 2020 15:13:00 -0400

SUZHOU, China – Genome editing startup Edigene Inc. and CAR T developer Immunochina Pharmaceuticals Co. Ltd., both from Beijing, have unveiled joint efforts to develop an allogeneic CAR T therapy for cancer. Terms remain undisclosed.

Edigene, Immunochina betting on allogeneic CAR T therapy in cancer collaboration

Thu, 28 May 2020 12:00:00 -0400

Cooperative research effort taking aim at genetics affecting COVID-19 infection

Tue, 28 Apr 2020 13:27:00 -0400

Cooperative research effort taking aim at genetics affecting COVID-19 infection

Tue, 28 Apr 2020 13:00:00 -0400

LONDON – Leading genome sequencing groups are launching the first meta-analysis in the hunt for genetic factors that explain why some people have worse COVID-19 symptoms than others, after agreeing to share patient sequence data from around the world. The COVID-19 Host Genetics Initiative (CHGI), set up by scientists at the Institute for Molecular Medicine Finland (FIMM), now includes 151 registered studies that are searching for genetic variation associated with severity and outcomes.

Cooperative research effort taking aim at genetics affecting COVID-19 infection

Tue, 28 Apr 2020 09:00:00 -0400